BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy. Nephrol Dial Transplant. 2013;28:1685-1693. [PMID: 23479095 DOI: 10.1093/ndt/gfs430] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Medjeral-Thomas N, Malik TH, Patel MP, Toth T, Cook HT, Tomson C, Pickering MC. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int. 2014;85:933-937. [PMID: 24067434 DOI: 10.1038/ki.2013.348] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.2] [Reference Citation Analysis]
2 Wang X, Van Lookeren Campagne M, Katschke KJ Jr, Gullipalli D, Miwa T, Ueda Y, Wang Y, Palmer M, Xing G, Song WC. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily. J Am Soc Nephrol 2018;29:2053-9. [PMID: 29895552 DOI: 10.1681/ASN.2018030270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
3 Yeter HH, Sütiçen E, Korucu B, Helvaci Ö, Özbaş B, Gönül İ, Derici Ü, Arinsoy T, Güz G. Evaluation of Clinical, Laboratory and Treatment Modalities in C3 Glomerulopathy: Single Center Experience. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2019;40:15-23. [PMID: 31605593 DOI: 10.2478/prilozi-2019-0010] [Reference Citation Analysis]
4 Devalaraja-Narashimha K, Meagher K, Luo Y, Huang C, Kaplan T, Muthuswamy A, Halasz G, Casanova S, O'Brien J, Peyser Boiarsky R, McWhirter J, Gartner H, Bai Y, MacDonnell S, Liu C, Hu Y, Latuszek A, Wei Y, Prasad S, Huang T, Yancopoulos G, Murphy A, Olson W, Zambrowicz B, Macdonald L, Morton LG. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy. J Am Soc Nephrol 2021;32:99-114. [PMID: 33288630 DOI: 10.1681/ASN.2020050698] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Yang Y, Denton H, Davies OR, Smith-Jackson K, Kerr H, Herbert AP, Barlow PN, Pickering MC, Marchbank KJ. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. J Am Soc Nephrol 2018;29:1649-61. [PMID: 29588430 DOI: 10.1681/ASN.2017091006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
6 Medjeral-Thomas N, Pickering MC. The complement factor H-related proteins. Immunol Rev. 2016;274:191-201. [PMID: 27782332 DOI: 10.1111/imr.12477] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
7 Koenderman L, Buurman W, Daha MR. The innate immune response. Immunol Lett 2014;162:95-102. [PMID: 25455595 DOI: 10.1016/j.imlet.2014.10.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
8 Andrighetto S, Leventhal J, Zaza G, Cravedi P. Complement and Complement Targeting Therapies in Glomerular Diseases. Int J Mol Sci 2019;20:E6336. [PMID: 31888179 DOI: 10.3390/ijms20246336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Ahmad A, Mandwie M, Dreismann AK, Smyth CM, Doyle H, Malik TH, Pickering MC, Lachmann PJ, Alexander IE, Logan GJ. Adeno-Associated Virus Vector Gene Delivery Elevates Factor I Levels and Downregulates the Complement Alternative Pathway In Vivo. Hum Gene Ther 2021. [PMID: 34238030 DOI: 10.1089/hum.2021.022] [Reference Citation Analysis]
10 Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. [PMID: 26221755 DOI: 10.1038/ki.2015.227] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
11 Detsika MG, Lianos EA. Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury. Antioxidants (Basel) 2021;10:60. [PMID: 33418934 DOI: 10.3390/antiox10010060] [Reference Citation Analysis]
12 Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol 2016; 5(4): 308-320 [PMID: 27458560 DOI: 10.5527/wjn.v5.i4.308] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hosoya M, Kawasaki Y, Maeda R, Sato M, Suyama K, Hashimoto K, Hosoya M. Predictive factors for poor outcome in pediatric C3 glomerulonephritis. Fukushima J Med Sci 2018;64:142-50. [PMID: 30369521 DOI: 10.5387/fms.2018-05] [Reference Citation Analysis]
14 Viswanathan GK, Nada R, Kumar A, Ramachandran R, Rayat CS, Jha V, Sakhuja V, Joshi K. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience. Diagn Pathol 2015;10:6. [PMID: 25889427 DOI: 10.1186/s13000-015-0233-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
15 Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol. 2014;27:457-460. [PMID: 24536001 DOI: 10.1007/s40620-013-0008-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
16 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
17 Corvillo F, Bravo García-Morato M, Nozal P, Garrido S, Tortajada A, Rodríguez de Córdoba S, López-Trascasa M. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy. Clin Exp Immunol 2016;184:118-25. [PMID: 26660535 DOI: 10.1111/cei.12754] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
18 Williams AL, Gullipalli D, Ueda Y, Sato S, Zhou L, Miwa T, Tung KS, Song WC. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy. Kidney Int 2017;91:1386-97. [PMID: 28139294 DOI: 10.1016/j.kint.2016.11.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
19 Nakano M, Karasawa K, Moriyama T, Uchida K, Nitta K. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center. Clin Exp Nephrol 2019;23:852-8. [PMID: 30854618 DOI: 10.1007/s10157-019-01716-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J. Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol. 2015;26:1503-1512. [PMID: 25694468 DOI: 10.1681/asn.2014101000] [Cited by in Crossref: 134] [Cited by in F6Publishing: 74] [Article Influence: 19.1] [Reference Citation Analysis]
21 Alexander JJ, Chaves LD, Chang A, Dighe S, Jacob A, Quigg RJ. Abrogation of immune complex glomerulonephritis by native carboxypeptidase and pharmacological antagonism of the C5a receptor. Cell Mol Immunol 2016;13:651-7. [PMID: 26166765 DOI: 10.1038/cmi.2015.45] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Andersen CA, Marcussen N, Gregersen JW. Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy. Clin Kidney J 2013;6:639-42. [PMID: 26069834 DOI: 10.1093/ckj/sft124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
24 Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, Willicombe M, McLean AG, Brookes P, Pusey CD, Falchi M, Cook HT, Pickering MC. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int 2017;92:942-52. [PMID: 28673452 DOI: 10.1016/j.kint.2017.03.043] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 10.8] [Reference Citation Analysis]
25 Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M, Suyama K, Hashimoto K, Hosoya M. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol 2016;31:1091-9. [DOI: 10.1007/s00467-015-3307-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kerns E, Rozansky D, Troxell ML. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr Nephrol. 2013;28:2227-2231. [PMID: 23892798 DOI: 10.1007/s00467-013-2565-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
28 Loeven MA, Rops AL, Berden JH, Daha MR, Rabelink TJ, van der Vlag J. The role of heparan sulfate as determining pathogenic factor in complement factor H-associated diseases. Molecular Immunology 2015;63:203-8. [DOI: 10.1016/j.molimm.2014.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kamel MH, Jaberi A, Gordon CE, Beck LH, Francis J. The Complement System in the Modern Era of Kidney Transplantation: Mechanisms of Injury and Targeted Therapies. Seminars in Nephrology 2022;42:14-28. [DOI: 10.1016/j.semnephrol.2022.01.006] [Reference Citation Analysis]
30 Wei L, Fang Y, Cao G, Zhang S, Tian M, Shen Q, Xu H, Liu C, Rao J. Genetic and pathological findings in a boy with psoriasis and C3 glomerulonephritis: A case report and literature review. Mol Genet Genomic Med 2020;8:e1430. [PMID: 32725812 DOI: 10.1002/mgg3.1430] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Masani N, Jhaveri KD, Fishbane S. Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014;9:600-608. [PMID: 24408117 DOI: 10.2215/cjn.06410613] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
32 Medjeral-Thomas NR, O'Shaughnessy MM. Complement in IgA Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy. Adv Chronic Kidney Dis 2020;27:111-9. [PMID: 32553243 DOI: 10.1053/j.ackd.2019.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Lioufas N, Finlay M, Barbour T. Durable remission of C3 glomerulonephritis with mycophenolate mofetil. Nephrology (Carlton) 2017;22 Suppl 1:36-9. [PMID: 28176473 DOI: 10.1111/nep.12939] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Gupta N, Wakefield DN, Clapp WL, Garin EH. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis. Nefrologia 2017;37:78-86. [PMID: 27595516 DOI: 10.1016/j.nefro.2016.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
35 Drake KA, Ellington N, Gattineni J, Torrealba JR, Hendricks AR. Clinicopathological features of C3 glomerulopathy in children: a single-center experience. Pediatr Nephrol 2020;35:153-62. [PMID: 31667615 DOI: 10.1007/s00467-019-04388-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Imamura H, Konomoto T, Tanaka E, Hisano S, Yoshida Y, Fujimura Y, Miyata T, Nunoi H. Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. Nephrology Dialysis Transplantation 2015;30:862-4. [DOI: 10.1093/ndt/gfv054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
37 Mathur M, Sharma S, Prasad D, Garsa R, Singh AP, Kumar R, Beniwal P, Agarwal D, Malhotra V. Incidence and profile of C3 Glomerulopathy: A single center study. Indian J Nephrol 2015;25:8-11. [PMID: 25684865 DOI: 10.4103/0971-4065.136889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
38 Prema KSJ, Kurien AA, Gopalakrishnan N, Walker PD, Larsen CP. Dense deposit disease: a greatly increased biopsy incidence in India versus the USA. Clin Kidney J 2019;12:476-82. [PMID: 31384437 DOI: 10.1093/ckj/sfy125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A 2019;116:7926-31. [PMID: 30926668 DOI: 10.1073/pnas.1820892116] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
40 Engelhardt JA, Fant P, Guionaud S, Henry SP, Leach MW, Louden C, Scicchitano MS, Weaver JL, Zabka TS, Frazier KS; Society of Toxicologic Pathology Vascular Injury Working Group. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides. Toxicol Pathol 2015;43:935-44. [PMID: 25717082 DOI: 10.1177/0192623315570341] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
41 Chuang HC, Chen YM, Hung WT, Li JP, Chen DY, Lan JL, Tan TH. Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. Oncotarget 2016;7:57593-605. [PMID: 27557500 DOI: 10.18632/oncotarget.11419] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
42 Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E. Treating C3 glomerulopathy with eculizumab. BMC Nephrol 2018;19:7. [PMID: 29329521 DOI: 10.1186/s12882-017-0802-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
43 Yurova VA, Bobrova LA, Kozlovskaya NL, Korotchaeva YV, Serova AG, Kozlov LV, Andina SS, Demyanova KA, Kuchieva AM, Roshchupkina SV. [Changes in the complement system in membranoproliferative glomerulonephritis]. Ter Arkh 2017;89:69-77. [PMID: 28745692 DOI: 10.17116/terarkh201789669-77] [Reference Citation Analysis]
44 Palamuthusingam D, Mantha M, Oliver K, Bavishi K, Dheda S. Mini review: A unique case of crescentic C3 glomerulonephritis. Nephrology (Carlton) 2017;22:261-4. [PMID: 28205354 DOI: 10.1111/nep.12925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Inman M, Prater G, Fatima H, Wallace E. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J. 2015;8:445-448. [PMID: 26251714 DOI: 10.1093/ckj/sfv044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
46 Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9:46-53. [PMID: 24178974 DOI: 10.2215/CJN.04700513] [Cited by in Crossref: 121] [Cited by in F6Publishing: 59] [Article Influence: 13.4] [Reference Citation Analysis]
47 Chaves LD, Bao L, Wang Y, Chang A, Haas M, Quigg RJ. Loss of CD11b exacerbates murine complement-mediated tubulointerstitial nephritis. PLoS One 2014;9:e92051. [PMID: 24632830 DOI: 10.1371/journal.pone.0092051] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
48 Georgievskaya Z, Nowalk AJ, Randhawa P, Picarsic J. Bartonella henselae endocarditis and glomerulonephritis with dominant C3 deposition in a 21-year-old male with a Melody transcatheter pulmonary valve: case report and review of the literature. Pediatr Dev Pathol 2014;17:312-20. [PMID: 24896298 DOI: 10.2350/14-04-1462-CR.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
49 Park S, Kim HW, Park JT, Chang TI, Kang EW, Ryu D, Yoo T, Chin HJ, Jeong HJ, Kang S, Lim BJ, Han SH. Relationship between complement deposition and the Oxford classification score and their combined effects on renal outcome in immunoglobulin A nephropathy. Nephrology Dialysis Transplantation 2020;35:2130-7. [DOI: 10.1093/ndt/gfz161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney International 2014;86:905-14. [DOI: 10.1038/ki.2014.49] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 8.9] [Reference Citation Analysis]
51 Frazier KS, Obert LA. Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney. Toxicol Pathol 2018;46:904-17. [PMID: 30089413 DOI: 10.1177/0192623318789399] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
52 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
53 Zhai YL, Meng SJ, Zhu L, Shi SF, Wang SX, Liu LJ, Lv JC, Yu F, Zhao MH, Zhang H. Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy. J Am Soc Nephrol 2016;27:2894-905. [PMID: 26825529 DOI: 10.1681/ASN.2015010012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
54 Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Córdoba SR, Noris M. The role of complement in C3 glomerulopathy. Mol Immunol. 2015;67:21-30. [PMID: 25929733 DOI: 10.1016/j.molimm.2015.03.012] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 8.6] [Reference Citation Analysis]